← Back to Search

Interactive Health Communication Application

MyCancerGene App for Cancer Genetic Testing Outcomes (MyCancerGene Trial)

N/A
Waitlist Available
Led By Angela R Bradbury, MD
Research Sponsored by Abramson Cancer Center at Penn Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
18 years of age or older
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline - 18 months
Awards & highlights

MyCancerGene Trial Summary

This trial will test whether a patient-centered genetic app can increase understanding of, and affective and behavioral responses to, genetic testing. The study hypothesis is that the intervention will be associated with increases in knowledge, decreases in distress, increases in communication with relatives and health care providers, and increases in performance of risk reducing health behaviors.

Who is the study for?
This trial is for men and women over 18 who have had genetic counseling and testing for hereditary cancer syndromes within the last 60 days. Participants must speak English and have access to the internet or a mobile device.Check my eligibility
What is being tested?
The trial is testing 'MyCancerGene,' an interactive health application designed to improve patient understanding of genetic testing results, reduce distress, encourage communication with family and healthcare providers, and promote risk-reducing behaviors.See study design
What are the potential side effects?
Since 'MyCancerGene' is an informational tool rather than a medication, it does not have physical side effects. However, learning about genetic risks can sometimes cause emotional or psychological distress.

MyCancerGene Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.

MyCancerGene Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline - 18 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline - 18 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Patient Reported Outcomes Measurement Information System (PROMIS)
The KnowGene Scale
Secondary outcome measures
Behavioral Risk Factor Surveillance System Questionnaire (BRFSS)
Health and Diet Survey Dietary Guidelines Supplement
Impact of Events Scale (IES)
+4 more

MyCancerGene Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Intervention GroupExperimental Treatment1 Intervention
Individuals randomized to this arm will receive immediate access to the Interactive Health Communication Application.
Group II: Usual Care GroupActive Control1 Intervention
Individuals randomized to this arm will receive the standard clinical practice.

Find a Location

Who is running the clinical trial?

Abramson Cancer Center at Penn MedicineLead Sponsor
383 Previous Clinical Trials
144,497 Total Patients Enrolled
American Cancer Society, Inc.OTHER
224 Previous Clinical Trials
110,057 Total Patients Enrolled
Abramson Cancer Center of the University of PennsylvaniaLead Sponsor
359 Previous Clinical Trials
104,741 Total Patients Enrolled

Media Library

MyCancerGene (Interactive Health Communication Application) Clinical Trial Eligibility Overview. Trial Name: NCT04774445 — N/A
Cancer Research Study Groups: Intervention Group, Usual Care Group
Cancer Clinical Trial 2023: MyCancerGene Highlights & Side Effects. Trial Name: NCT04774445 — N/A
MyCancerGene (Interactive Health Communication Application) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04774445 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the intended outcomes of this research?

"This trial has two primary objectives: to evaluate patients using the KnowGene Scale, and to measure changes in uncertainty with the Multi-dimensional Impact of Cancer Risk Assessment Questionnaire (MICRA). Secondary evaluation includes assessing shifts in perceived risk, timeline and utility through quantitative scales as well as Yes/No responses for dietary guidelines. The study will span a period of 18 months from baseline."

Answered by AI

Are there any vacancies available for participants in this trial?

"According to details provided on clinicaltrials.gov, this study is currently enrolling participants. Initially published on May 3rd 2021, the trial was most recently updated July 11th 2022."

Answered by AI

How many participants is the medical trial accepting at this time?

"Affirmative, clinicaltrials.gov has evidence that this research trial is actively recruiting participants. It was initially posted on May 3rd 2021 and the last update occured on July 11th 2022. 400 individuals must be admitted at a single medical centre to meet their recruitment goals."

Answered by AI

Who else is applying?

What state do they live in?
Pennsylvania
How old are they?
18 - 65
What site did they apply to?
Abramson Cancer Center at the University of Pennsylvania
What portion of applicants met pre-screening criteria?
Met criteria

How responsive is this trial?

Typically responds via
Email
~0 spots leftby Apr 2024